Cargando…
Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237008/ https://www.ncbi.nlm.nih.gov/pubmed/37274378 http://dx.doi.org/10.4330/wjc.v15.i5.217 |
_version_ | 1785053068089360384 |
---|---|
author | Grillo, Thais Gagno Silveira, Caroline Ferreira da Silva Mazeto Pupo Quaglio, Ana Elisa Valencise Dutra, Renata de Medeiros Baima, Julio Pinheiro Bazan, Silmeia Garcia Zanati Sassaki, Ligia Yukie |
author_facet | Grillo, Thais Gagno Silveira, Caroline Ferreira da Silva Mazeto Pupo Quaglio, Ana Elisa Valencise Dutra, Renata de Medeiros Baima, Julio Pinheiro Bazan, Silmeia Garcia Zanati Sassaki, Ligia Yukie |
author_sort | Grillo, Thais Gagno |
collection | PubMed |
description | Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the exact mechanism of development of HF remains obscure. TNFα is found in both healthy and damaged hearts. Its effects are concentration- and receptor-dependent, promoting either cardio-protection or cardiomyocyte apoptosis. Experimental rat models with TNFα receptor knockout showed increased survival rates, less reactive oxygen species formation, and improved diastolic left ventricle pressure. However, clinical trials employing anti-TNF therapy to treat HF had disappointing results, suggesting abolishment of the cardioprotective properties of TNFα, making cardiomyocytes susceptible to apoptosis and oxidation. Thus, patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy. This review aims to discuss adverse events associated with the administration of anti-TNF therapy, with a focus on HF, and propose some approaches to avoid cardiac adverse events in patients with IBD. |
format | Online Article Text |
id | pubmed-10237008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-102370082023-06-03 Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature Grillo, Thais Gagno Silveira, Caroline Ferreira da Silva Mazeto Pupo Quaglio, Ana Elisa Valencise Dutra, Renata de Medeiros Baima, Julio Pinheiro Bazan, Silmeia Garcia Zanati Sassaki, Ligia Yukie World J Cardiol Minireviews Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the exact mechanism of development of HF remains obscure. TNFα is found in both healthy and damaged hearts. Its effects are concentration- and receptor-dependent, promoting either cardio-protection or cardiomyocyte apoptosis. Experimental rat models with TNFα receptor knockout showed increased survival rates, less reactive oxygen species formation, and improved diastolic left ventricle pressure. However, clinical trials employing anti-TNF therapy to treat HF had disappointing results, suggesting abolishment of the cardioprotective properties of TNFα, making cardiomyocytes susceptible to apoptosis and oxidation. Thus, patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy. This review aims to discuss adverse events associated with the administration of anti-TNF therapy, with a focus on HF, and propose some approaches to avoid cardiac adverse events in patients with IBD. Baishideng Publishing Group Inc 2023-05-26 2023-05-26 /pmc/articles/PMC10237008/ /pubmed/37274378 http://dx.doi.org/10.4330/wjc.v15.i5.217 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Grillo, Thais Gagno Silveira, Caroline Ferreira da Silva Mazeto Pupo Quaglio, Ana Elisa Valencise Dutra, Renata de Medeiros Baima, Julio Pinheiro Bazan, Silmeia Garcia Zanati Sassaki, Ligia Yukie Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title | Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title_full | Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title_fullStr | Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title_full_unstemmed | Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title_short | Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature |
title_sort | acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237008/ https://www.ncbi.nlm.nih.gov/pubmed/37274378 http://dx.doi.org/10.4330/wjc.v15.i5.217 |
work_keys_str_mv | AT grillothaisgagno acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT silveiracarolineferreiradasilvamazetopupo acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT quaglioanaelisavalencise acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT dutrarenatademedeiros acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT baimajuliopinheiro acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT bazansilmeiagarciazanati acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature AT sassakiligiayukie acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature |